Navigation Links
Asterias Biotherapeutics Announces Intention to Distribute 3.15 Million Warrants to Purchase Common Shares of Asterias to Asterias Shareholders
Date:2/16/2016

FREMONT, Calif., Feb. 16, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today simplified its capital structure through the previously announced Asset Swap with BioTime, Inc. In conjunction with the Asset Swap, Asterias also announces its intention, at its discrestion, to distribute the 3.15 million warrants to purchase common shares of Asterias received pursuant to the Asset Swap to Asterias shareholders on terms to be determined by its Board of Directors.

"I am pleased to announce that Asterias ended 2015 with approximately $21 million of cash, cash equivalents and marketable securities," said Pedro Lichtinger, President and CEO of Asterias. "After the upcoming distribution, if the holders exercise their warrants, we believe Asterias will have the cash it needs to fund operations for at least the next 12 months. In addition, BioTime's ownership of Asterias would be reduced from 58% to 54%." 

About Asterias Biotherapeutics

Asterias Biotherapeutics, Inc. is a leading biotechnology company in the emerging field of regenerative medicine. The company's proprietary, industry leading platforms are based on its pluripotent stem cell and dendritic cell immunotherapy technologies. Asterias is focused on developing therapies to treat conditions in several medical areas where there is high unmet medical need and inadequate available therapies. AST-OPC1 (oligodendrocyte progenitor cells) is currently in a Phase 1/2a dose escalation clinical trial in spinal cord injury. AST-VAC1 (antigen-presenting autologous dendritic cells) has demonstrated promise in a Phase 2 study in acute myelogenous leukemia. AST-VAC2 (antigen-presenting allogeneic dendritic cells) represents a second generation, allogeneic approach to dendritic cell vaccines. Additional information about Asterias can be found at www.asteriasbiotherapeutics.com.

FORWARD-LOOKING STATEMENTS 
Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Asterias, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the businesses of Asterias, particularly those mentioned in the cautionary statements found in Asterias's filings with the Securities and Exchange Commission. Asterias disclaims any intent or obligation to update these forward-looking statements.

 

 

 


'/>"/>
SOURCE Asterias Biotherapeutics, Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related biology technology :

1. Asterias Biotherapeutics to Report Third Quarter Results on November 9, 2015
2. Asterias Biotherapeutics to Begin Dose Escalation in the SCiStar Phase 1/2a Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury
3. Asterias Biotherapeutics to Present at 2015 Stem Cell Meeting on the Mesa
4. Asterias Biotherapeutics Announces Publication of Preclinical Data that Supports the Safety and Use of AST-OPC1 as a Treatment for Spinal Cord Injury (SCI)
5. Asterias Biotherapeutics to Present at Upcoming Investor Conferences
6. Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML)
7. Asterias Biotherapeutics Receives $11.7 Million in Proceeds from Exercise of Warrants
8. Asterias Biotherapeutics Reports First Quarter Results
9. Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015
10. Asterias Biotherapeutics Announces Change to Presentation Time at Needham Healthcare Conference
11. Asterias Biotherapeutics Reports Fourth Quarter and Full Year 2014 Financial and Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)... ... May 16, 2017 , ... Clinical Supplies Management (“CSM”), a ... the company continues to grow. CSM has doubled in size over the past ... an aggressive growth strategy. , Roger Gasper joins CSM as Chief Financial Officer. ...
(Date:5/18/2017)... (PRWEB) , ... May 17, ... ... CRO standards with psychonneuroendocrine stress expertise, and further enhances its scientific power ... researcher, Douglas A. Granger, Ph.D., has agreed to join the scientific advisory ...
(Date:5/18/2017)... ... May 17, 2017 , ... USDM Life Sciences , ... life sciences and healthcare industries, is honored that Jay Crowley was ... in Brussels, Belgium. , Crowley played a crucial role in the development of ...
(Date:5/18/2017)... ... May 17, 2017 , ... ... that their Chief Executive Officer, Maik Jornitz, was recognized as a Top 10 ... List celebrates 100 individuals “involved in bettering the pharma industry and bringing life-changing ...
Breaking Biology Technology:
(Date:5/16/2017)... , May 16, 2017   Bridge ... health organizations, and MD EMR Systems , ... development partner for GE, have established a partnership ... Portal product and the GE Centricity™ products, including ... EMR. These new integrations will ...
(Date:4/18/2017)... Calif. , April 18, 2017  Socionext Inc., a global ... of a media edge server, the M820, which features the company,s ... recognition software provided by Tera Probe, Inc., will be showcased during ... at the NAB show at the Las Vegas ... ...
(Date:4/11/2017)... GARDENS, Fla. , April 11, 2017 /PRNewswire/ ... management and secure authentication solutions, today announced that ... by Intelligence Advanced Research Projects Activity (IARPA) to ... IARPA,s Thor program. "Innovation has been ... and IARPA,s Thor program will allow us to ...
Breaking Biology News(10 mins):